[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"generalized-pustular-psoriasis-gpp\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:generalized-pustular-psoriasis-gpp":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100627422","generalized-pustular-psoriasis-registry-in-costa-rica-100627422",false,"NCT07448428","Generalized Pustular Psoriasis Registry in Costa Rica","National Registry of Patients With Generalized Pustular Psoriasis Treated Within the Costa Rican Social Security System","Inclusion Criteria:\n\n* Confirmed diagnosis of generalized pustular psoriasis (GPP) established by a board-certified dermatologist based on compatible clinical and\u002For histopathologic criteria.\n* Registered diagnosis of GPP in the institutional electronic health record system (EDUS code L401) during the study period.\n* Patients of any age and sex receiving care within participating centers of the Costa Rican Social Security system.\n* Availability of clinical information sufficient for registry data entry and follow-up according to routine care.\n\nExclusion Criteria:\n\n* Patients without a confirmed diagnosis of generalized pustular psoriasis (GPP) or with alternative pustular dermatoses (e.g., acute generalized exanthematous pustulosis) not meeting GPP diagnostic criteria.\n* Absence of verifiable diagnosis in the institutional electronic health record (EDUS) or insufficient documentation to confirm GPP.\n* Patients whose clinical records lack the minimum data required for registry variables or follow-up within routine care.","ALL",{"count":18,"type":19},50,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this observational registry study is to characterize the clinical, epidemiological, and therapeutic features of patients with generalized pustular psoriasis (GPP) in Costa Rica through a standardized national registry. The main question it aims to answer is:\n\nWhat are the clinical, epidemiological, and therapeutic characteristics of patients with generalized pustular psoriasis registered in the country, and how do these relate to disease severity and evolution?\n\nPatients with GPP receiving routine dermatologic care in participating centers will have their demographic, clinical, severity, comorbidity, and treatment data recorded using a standardized case report form. Clinical assessments (e.g., GPPASI, PASI\u002FBSA, DLQI), laboratory results, triggers, complications, and therapies will be documented and updated during periodic follow-up visits as part of usual care.",[24,25],"Generalized Pustular Psoriasis","Generalized Pustular Psoriasis (GPP)",[27,28,29,30],"Psoriasis","Registry","Costa Rica","Generalized pustular psoriasis","NOT_YET_RECRUITING","2026-03-06",{"date":34,"type":35},"2026-03-09","ACTUAL",{"date":37,"type":19},"2026-05",{"date":39,"type":19},"2031-05",{"name":41,"class":42},"Caja Costarricense de Seguro Social","OTHER_GOV",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":5},"100533865","phase-2-efficacy-and-safety-of-hb0034-in-patients-with-generalized-pustular-psoriasis-gpp-100533865","NCT06231381","Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)","A Phase II, Multicenter, Double-blind, Randomized, Placebo Parallel-controlled Trial to Evaluate the Efficacy and Safety of HB0034 in Patients with GPP Presenting with an Acute Flare of Moderate to Severe Intensity","Inclusion Criteria:\n\n* Patients must be experiencing an acute GPP flare of moderate-to-severe intensity at baseline, defined as:\n\n  1. A Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score of ≥ 3;\n  2. New appearance or worsening of existing pustules, and a GPPGA pustulation subscore of ≥ 2;\n  3. ≥ 5% Body Surface Area (BSA) covered with pustules.\n* Men and women of reproductive age who have no parenting plans and are willing to use reliable contraception during the study period and for 6 months after the last dose of the study drug;\n* Patients who fully understand and voluntarily sign an ICF, and are willing and able to follow clinical study and subsequent visit schedules.\n\nExclusion Criteria:\n\n* Drug-triggered acute generalized exanthematous pustulosis (AGEP);\n* Synovitis-acne-pustulosis-hyperostosis-osteitis syndrome (SAPHO);\n* Other active inflammatory or autoimmune diseases requiring systemic treatment with immunosuppressants, including but not limited to rheumatoid arthritis (RA), psoriatic arthritis (PsA), systemic lupus erythematosus (SLE), inflammatory bowel disease, and uveitis.\n* Patients with an increased risk of infectious complications as assessed by the investigator (e.g., a recent suppurative infection, any congenital or acquired immunodeficiency, such as HIV infection, prior organ or stem cell transplantation);\n* Patients who have received a live vaccine or investigational live vaccine within 6 weeks prior to the first dose of the study drug, or plan to receive a live vaccine or participate in a clinical study of investigational live vaccine during the study period or within 6 weeks after completion of administration of the study drug;\n* Patients who have had a serious trauma or undergone a major surgery within 1 month prior to the first dose of the study drug, or plan to undergo any elective surgery during the study period;\n* Patients with documented active or suspected malignancy or a history of malignancy within 5 years prior to screening;\n* Patients with a history of severe allergy, who have experienced grade 3-4 allergic reactions when receiving other monoclonal antibodies, or those who are known to have hypersensitivity to protein drugs, recombinant proteins, or HB0034 components;\n* Subjects who are pregnant or breastfeeding, or those who have a positive pregnancy test result. Breastfeeding female subjects who stop breastfeeding prior to the first dose of the study drug until 16 weeks after the end of the trial will not be excluded;\n* Patients who are currently participating in clinical trials or have participated in clinical trials of any drug\u002Fdevice within 30 days (or 5 half-lives, whichever is longer) prior to the first dose of the study drug;\n* Patients expected to have poor compliance, such as those who are uncooperative, fail to receive follow-up on time, and are unlikely to complete the study;\n* Other reasons that the investigator considers it is inappropriate to participate in the study.","18 Years","75 Years",{"count":54,"type":19},33,"INTERVENTIONAL",[57],"PHASE2","This is a phase II, multicenter, double-blind, randomized, placebo parallel-controlled clinical trial to evaluate the efficacy and safety of HB0034 in patients with generalized pustular psoriasis (GPP) presenting with an acute flare of moderate to severe intensity.",[25],"RECRUITING","2025-03-18",{"date":63,"type":35},"2025-03-19",{"date":65,"type":35},"2024-02-29",{"date":67,"type":19},"2025-11-30",{"name":69,"class":70},"Shanghai Huaota Biopharmaceutical Co., Ltd.","INDUSTRY"]